There are 2789 resources available
852P - Feasibility and safety of HiDAC in AML patients who have achieved CR with hypomethylating agents: Prospective study
Presenter: Sanjo Varghese
Session: ePoster Display
Resources:
Abstract
853P - PRAME expression and ImmTAC TCR bispecific sensitivity in acute myeloid leukaemia in the presence and absence of the hypomethylating agent decitabine
Presenter: Camille Britton-Rivet
Session: ePoster Display
854P - Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Presenter: Mrinal Patnaik
Session: ePoster Display
855P - Exploring the cardio-cerebrovascular outcomes and thromboembolic risks among BCR-ABL1-negative myeloproliferative neoplasms treated with ruxolitinib: Systematic review and meta-analysis
Presenter: Boby Pratama Putra
Session: ePoster Display
856P - A comparison of the burden of leukemia amongst European Union 15+ countries, 1990-2019
Presenter: Chinmay Jani
Session: ePoster Display
707P - Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma: Results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017
Presenter: Jorgen Bjerggaard Jensen
Session: ePoster Display
1092TiP - Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
Presenter: Reinhard Dummer
Session: ePoster Display
1093TiP - An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
Presenter: Francesca Aroldi
Session: ePoster Display
1094TiP - A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
Presenter: Andrew Haydon
Session: ePoster Display